Clinical Trial Update: A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of crenolanib with chemotherapy in newly diagnosed AML patients with FLT3 mutations completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Newly Diagnosed AML With FLT3 Activating Mutations | Phase 2 | Status: COMPLETED | Results posted: 2024-02-02